Neurotrophic Bone Marrow Cellular Nests Prevent Spinal Motoneuron Degeneration in Amyotrophic Lateral Sclerosis Patients: A Pilot Safety Study

• Published in: Stem cells (Dayton, Ohio) Vol. 30; no. 6; pp. 1277 - 1285
• Main Authors: Blanquer, Miguel, Moraleda, Jose M., Iniesta, Francisca, Gómez-Espuch, Joaquín, Meca-Lallana, José, Villaverde, Ramón, Pérez-Espejo, Miguel Ángel, Ruíz-López, Francisco José, García Santos, José María, Bleda, Patricia, Izura, Virginia, Sáez, María, De Mingo, Pedro, Vivancos, Laura, Carles, Rafael, Jiménez, Judith, Hernández, Joaquín, Guardiola, Julia, Del Rio, Silvia Torres, Antúnez, Carmen, De La Rosa, Pedro, Majado, Maria Juliana, Sánchez-Salinas, Andrés, López, Javier, Martínez-Lage, Juan Francisco, Martínez, Salvador
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.06.2012; Oxford University Press
• Subjects: Adult; Adult stem cells; Amyotrophic lateral sclerosis; Amyotrophic Lateral Sclerosis - pathology; Amyotrophic Lateral Sclerosis - surgery; Bone marrow; Bone Marrow Cells - pathology; Bone Marrow Transplantation - methods; Clinical trials; Female; Humans; Male; Middle Aged; Motor Neurons - pathology; Nerve Degeneration - pathology; Pilot Projects; Somatic cell therapy; Spinal Cord - pathology; Spinal Cord - surgery; Stem cell transplantation
• ISSN: 1066-5099; 1549-4918
• DOI: 10.1002/stem.1080

The objective of this article is to assess the safety of intraspinal infusion of autologous bone marrow mononuclear cells (BMNCs) and, ultimately, to look for histopathological signs of cellular neurotrophism in amyotrophic lateral sclerosis (ALS) patients. We conducted an open single arm phase I trial. After 6 months observation, autologous BMNCs were infused into the posterior spinal cord funiculus. Safety was the primary endpoint and was defined as the absence of serious transplant‐related adverse events. In addition, forced vital capacity (FVC), ALS‐functional rating scale (ALS‐FRS), Medical Research Council scale for assessment of muscle power (MRC), and Norris scales were assessed 6 and 3 months prior to the transplant and quarterly afterward for 1 year. Pathological studies were performed in case of death. Eleven patients were included. We did not observe any severe transplant‐related adverse event, but there were 43 nonsevere events. Twenty‐two (51%) resolved in ≤2 weeks and only four were still present at the end of follow‐up. All were common terminology criteria for adverse events grade ≤2. No acceleration in the rate of decline of FVC, ALS‐FRS, Norris, or MRC scales was observed. Four patients died on days 359, 378, 808, and 1,058 post‐transplant for reasons unrelated to the procedure. Spinal cord pathological analysis showed a greater number of motoneurons in the treated segments compared with the untreated segments (4.2 ± 0.8 motoneurons per section [mns per sect] and 0.9 ± 0.3 mns per sect, respectively). In the treated segments, motoneurons were surrounded by CD90+ cells and did not show degenerative ubiquitin deposits. This clinical trial confirms not only the safety of intraspinal infusion of autologous BMNC in ALS patients but also provides evidence strongly suggesting their neurotrophic activity. STEM CELLS2012;30:1277–1285